Turn released an updated investor presentation highlighting a Q4 2026 topline readout for GX-03 and a cash balance of $11.2M as of March 31, 2026.Key Highlights:Original SEC Filing: Turn Therapeutics Inc. [ TTRX ] - 8-K - Jul. 28, 2026This is an AI-powered summary. It may contain inaccuracies. Cons…
GX-03 phase II trial for atopic dermatitis advances to an optimized stage two after interim analysis showed strong efficacy and safety, especially in patients with higher pruritus scores. The study uses a stratified, adaptive design and targets a phase II readout in Q4 2026.Based on Turn Therapeuti…
Turn Therapeutics announced an optimized, expanded Stage 2 design for its GX-03 Phase 2 atopic dermatitis trial after a comprehensive interim analysis showing meaningful efficacy across the full EASI severity spectrum.Key Highlights:Original SEC Filing: Turn Therapeutics Inc. [ TTRX ] - 8-K - Jul…
By Elias SchisgallShares of Turn Therapeutics climbed ahead of the company's release of initial findings from a phase 2 trial of GX-03, its treatment for atopic dermatitis.Shares were up 2.9%, to $7.91, in after-hours trading Monday. The stock closed up 8%, at $7.69, having nearly doubled in value…
